Doximity Joins Fireworks AI Benchmarks, Launches Bedside Bench Open-Source AI Test
Sep 22, 2026, 7:19 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Positive signal for DOCS' AI leadership perception and potential monetization channels, though no immediate revenue guidance; likely limited near-term price move unless Bedside Bench adoption translates into tangible product revenue.
AI summary
What happened, with direct paths to the underlying reporting
Doximity is a founding partner in Fireworks' Specialized Intelligence Index and will publish Bedside Bench, an open-source benchmark for clinical-grade AI. The move broadens DOCS' AI footprint and could deepen engagement with healthcare AI developers, though immediate revenue impact is unclear and depends on Bedside Bench adoption.
Doximity named founding partner in new AI benchmarks index by Fireworks. Bedside Bench opens-source benchmark for clinical AI testing.
Bedside Bench open-source benchmark measures clinical-grade AI performance. Aims to standardize AI evaluation in healthcare.
Expands DOCS' AI strategy beyond physician directory with partnerships in AI benchmarks. No immediate revenue guidance provided.
Announcement signals potential longer-term collaboration opportunities and data-network effects for DOCS.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
A new securities-class-action targets Doximity (DOCS), asserting the Newsfeed was overstated as a revenue driver and contributing to a May 2026 revenue miss. The suit, if pursued…
Doximity reported Q1 results with an earnings miss but raised full-year revenue guidance, highlighting stronger AI-driven engagement. Analysts turned more bullish on improving gro…
Doximity delivered a mixed Q4 with soft full-year guidance as the HCP digital pharma ad market faces policy and macro headwinds. Management guides modest growth at or below 5% thi…
Doximity's Q4 earnings missed expectations, prompting significant analyst downgrades and lower future revenue guidance. The stock is struggling at a new 52-week low, indicating on…